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Summary A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine
differentiation, has been evaluated in small cell lung cancer (SCLC). In untreated patients 25/38 (68%) with
localized SCLC had raised blood levels of NSE (>13 ngml-1), in extensive disease 34/39 (87%) patients had
raised NSE levels. In patients with non-small cell lung cancer (NSCLC) the serum levels were raised in 16/94
(17%). In extensive tumours of non-pulmonary origin NSE levels were increased in 24/116 (20%) patients.
Longitudinal studies indicated a good correlation between the response to chemotherapy and fall of NSE
levels. Tumour progression was accompanied by a rising NSE in 25/29 patients, with doubling times of 7-90
days. In patients with progression with a normal NSE the recurrence was a NSCLC. Cerebral metastases
occurring as the only recurrence during clinical complete remission were not accompanied by a rise of NSE.
Serum NSE levels provides a valuable monitor for SCLC during and after chemotherapy.
Enolase is a glycolytic enzyme [EC 4.2.1.11] that is
composed of sub units a, ,B & y. Neuron specific
enolase [NSE] is the yy dimer of enolase
(Marangos et al., 1979). There is growing evidence
that the histochemical demonstration of immuno-
reactive neuron specific enolase (NSE) in tumour
cells can be used as an indicator of their likely
neural or neuroendocrine origin. Biochemically
these cells are characterised as possessing amine
precursor uptake and decarboxylation (APUD)
enzyme systems and the production of various
hormones and peptides.
Tumours arising from the neuroendocrine cell
system that contain NSE include, small cell lung
cancer (SCLC) (Marangos et al., 1982; Sheppard et
al., 1984; Springhall et al., 1984) and some
comparative rare cancers such as neuroblastoma
(Odelstad et al., 1982; Tsokos et al., 1984; Zeltzer et
al., 1983) pancreatic islet cell cancers (Simpson et
al., 1984; Lloyd et al., 1984) carcinoid tumours
(Sheppard et al., 1984) and medullary thyroid
carcinoma (Lloyd et al., 1983). Several immuno-
assay methods have been described for NSE in
body fluids. The results of assays of serum NSE
using the radioimmunoassay (RIA) devised by
Marangos and his colleagues have been published
for several types of tumours of neuroendocrine
origin (Carney et al., 1982; Prinz et al., 1983; Zeltzer
et al., 1983). Other assays include further RIAs
(Pahlman et al., 1984; Royds et al., 1984) including
assays depending on the cross reactivity of an anti-
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rat NSE antiserum and human NSE (Kato et al.,
1983), or anti-mouse NSE and human NSE (Akoun
et al., 1985) and immunobioluminescence assays
(Wevers et al., 1983; Gerbitz et al., 1984).
Small cell lung cancer is the commonest type of
tumour showing neuroendocrine differentiation.
The measurement of serum NSE has shown to be of
value in monitoring SCLC (Carney et al., 1982;
Pahlman et al., 1984; Esscher et al., 1985; Kato et
al., 1983; Akoun et al., 1985; Ariyoshi et al., 1983;
Johnson et al., 1984).
Recently Pharmacia, Sweden have introduced a
radioimmunoassay which provides the opportunity
for a wide based large scale assessment of the role
of NSE measurements in oncology. This paper
describes an evaluation of the Pharmacia NSE-RIA
assay in the assessment and monitoring of SCLC.
Materials and methods
Patients One hundred and seventy one patients
with lung cancer were examined at presentation
before treatment. They included 77 SCLC and 94
non-small cell carcinoma of the lung (NSCLC) (11
adeno- 69 squamous, and 15 large cell). Patients
were staged as having limited disease (disease
confined to one hemithorax and mediastinal lymph-
nodes) or extensive disease (any spread outside
these regions).
Various control groups were examined including
33 blood donors, 20 advanced cancers of breast and
gastrointestinal origin with liver metastases, 42
disseminated prostatic cancer, 45 benign gastro-
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intestinal disease, 20 bronchopneumonia, 14 patients
with benign lesions of the lung that were con-
sidered as possible lung cancers prior to biopsy and
10 patients with lung metastases from distant sites.
Longitudinal studies were made of specimens
obtained from 37 patients with SCLC, 19 from the
start of treatment, and 18 commenced at various
times after initiating chemotherapy. The follow up
period was 4-28 months (average 10.5 months) with
the sampling generally every 4-6 weeks according
to the treatment protocol. The total samples per
patient varied from 6 to 19. Thirty three patients
were treated with CAVP (Cyclophosphamide
1000mgm-2 day 1 i.v. Adriamycin 45mgm-2 day
1 i.v., VP 16:213 lOOmgm-2 days 1, 3 and 5 i.v.)
repeated every 3 weeks. In these studies commenced
in 1982, samples of heparin plasma had been stored
at each visit to the clinic. A further four patients
were studied longitudinally, three were treated with
ifosfamide, VP 16:213 and vincristine, and one
received radiotherapy alone; in these patients serum
was measured.
The serum and heparin plasma samples were
stored at -20°C prior to analysis. Haemolysed
samples were not used as they could be a source of
a false elevation of NSE (Pahlman et al., 1984,
Johnson et al., 1984).
An estimate of the inflammatory response to the
combined effects of tumour tissue destruction and
infection was obtained from the serum C-reactive
protein (CRP) level measured by radial immuno-
diffusion.
The Pharmacia NSE RIA test is a double
antibody radio-immunoassay. NSE in the sample
competes with a fixed amount of 125I-labelled NSE
for the binding sites of the specific antibodies
(present in limited amount). Bound and free NSE
are separated by the use of a second antibody
covalently bound to spherical particles of agarose.
After addition of the agarose antibody derivative,
the mixture is centrifuged. The supernatant with the
free NSE is then separated from the agarose pellet
containing the bound NSE by decanting. The
removal of the liquid phase can be done
quantitatively and without extra washing. The
radioactivity in the pellet is then measured. It is
inversely proportional to the quantity of NSE in
the sample. The detection limit is <2.6ngml-1, the
measuring range 3.2-260ngml-1 with an average
analysis time of 6h for a batch of 40 samples.
The suggested upper limit of normal is 12.5ngmlP .
Results
The mean +s.d. serum NSE level in 33 blood
donors was 9.3 +2.1 ngml -. The NSE-RIA test
showed a coefficient of variation of 12.5% between
assays and 9.8% within assays over a range of 4-
100ngml-'. The manufacturer stated that the kit
has a coefficient of variation of 7.6% between assays
and 5.8% within assay for a serum with an NSE
content of 13.6ngml-'.
Presentation data
The distribution of NSE levels in patients with
SCLC and NSCLC, subdivided according to histo-
logical type and extent of the disease are shown in
Figure 1. These are contrasted to the NSE levels in
patients with lung lesions considered as possible
lung cancer and demonstrated to be benign. It is
evident that the levels of NSE in SCLC are
generally considerably higher than in other forms of
lung cancer. The median serum NSE concentration
for SCLC was 14ngml-' and 42ngml- ' in
patients with limited and extensive disease
respectively. This contrasts to a median level of
7.2ngml-1 and 9.1ngml-1 in patients with limited
and extensive NSCLC respectively. The incidence of
raised levels of NSE> 13 ngml-1 in other forms
cancer and benign disease was low as shown in
Table I. In bronchopneumonia and all forms of
cancer there was no correlation between the CRP
level and the serum NSE level (r=0.04, P=0.78).
The median level was 7.5 ngml-1 in 11 patients
with lesions suspicious of lung cancer that were
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Figure 1 Distribution of NSE levels in patients with
lung cancer at presentation. (0) serum; (0) heparin
plasma. L =localized disease; E =extensive disease.
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Table I NSE levels in lung cancer, various benign and malignant diseases and blood donors
<13 13-25 25-50 >50
Serum NSE ngmlr- (%) (%) (%) (%)
Blood donors (33) 31 (94) 2 (6)
SCLC pre-treatment
limited disease (38) 13 (34.3) 9 (23.7) 11 (28.9) 5 (13.2)
extensive disease (39) 5 (12.8) 4 (10.2) 12 (30.8) 18 (46.2)
Non SCLC (94) 78 (83) 9 (9.5) 3 (3.2) 4 (4.2)
Metastatic tumours in the lung (10) 8 (80) 2 (20)
Benign lesions oflung (11) 10 (91) 1 (9)
Bronchopneumonia (20) 13 (65) 6 (30) 1 (5)
Benign gastrointestinal and liver disease (45) 38 (84.4) 7 (15.6)
Breast and gastrointestinal cancer with hepatic mets. (20) 17 (85) 3 (15)
Metastatic carcinoma of prostate (42) 31 (73.8) 8 (19) 3 (7.2)
eventually shown to be benign and 9.4ngml-' in
bronchopneumonia. In 10 patients with lung
metastases, from a variety of primary tumours, the
median level was 5.6ngml-1, and all were
< 15ngml '.
I- Chemotherapy I
100 -
Longitudinal studies
Several patterns of response could be recognised,
these were identified in the 23 patients who were
studied from presentation the rarest being
persistently high NSE after giving chemotherapy; 2
out of 23 (8.6%) of cases observed from
presentation demonstrated this pattern. More
commonly the NSE level gradually fell to reach a
plateau after 2-6 courses of chemotherapy. In 4
patients the level fell to normal after a single
course of chemotherapy. Several patients showed
oscillating levels initially during the first few
courses of treatment, NSE levels subsequently
reached a low plateau. An example of the rapid fall
patterns is shown in Figure 2, the gradual decline
of NSE during chemotherapy is shown in Figure 3.
The patient treated by radiotherapy alone had an
NSE that fell from 40ngml-1 to 7.Ongml'- within
1 month of treatment.
Nine patients including the 4 who responded
rapidly were judged as being in complete remission
after ending their chemotherapy, they were then
followed for 6-22 months. Six out of 68 NSE
(8.8%) measurements in these patients were
unexpectedly high on a single occasion but the
subsequent observations were all <15ngml-1
whilst the patients remained in clinical complete
remission.
In 8 patients who developed brain metastases at
a time when the disease had been in clinical
remission the NSE levels remained normal.
Twenty-five out of 29 patients (15 of whom had
been followed from presentation) who were
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Figure 2 Serial NSE levels in a patient with extensive
SCLC. After one course of chemotherapy NSE levels
rapidly falls to normal levels, reaches a plateau for 90
days and then rises with a doubling time of 34 days.
No response is induced by the original chemotherapy 6
or salvage chemotherapy 7.
clinically progressive with disease outside the brain
had exponentially rising NSE levels, which preceded
the clinical detection of progressive disease by 0-
112 days (median 42 days). Examples of the rates
of change of NSE are shown in Figure 4 the
doubling time of those illustrated were 20-50 days,
but the extremes were 7-90 days. Three of these 29
patients had a relapse confirmed histologically to be
of a NSCLC, and one patient had clinical
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Figure 3 Serial NSE levels in a patient with limited SCLC. After the start of chemotherapy NSE first rises,
then slowly declines. After 4 courses of chemotherapy the NSE reaches a plateau for 197 days and then rises
with a doubling time of 88 days. Radiotherapy given to the tumour and prophylatically to the brain.
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Figure 4 A comparison of the rates of increase of
NSE during the evolution of relapsed SCLC.
progressive disease without a concomitant rise of
NSE.
The serial measurement of CRP did not provide
a sensitive tumour marker, but confirmed that the
NSE levels were unaffected by infection.
Discussion
A raised serum NSE or heparin plasma
(>13ngml-') as assayed by the Pharmacia NSE-
RIA was observed in 77% of patients with SCLC
at presentation. A comparison of the present data
with published series is shown in Table II. Showing
that the test gives results similar to those reported
using a variety of immunoassays for NSE. Large
cell undifferentiated lung cancers, which may be
confused with SCLC are shown to have high NSE
levels in this study and by Ariyoshi et al. (1983)
and Pahlman et al. (1983). Therefore a higher cut
off value than in the present study would seem
advisable when using the test to indicate that a
tumour may be a SCLC in those cases where the
biopsy was equivocal, technically unsatisfactory or
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Table II Frequency of raised serum NSE levels in SCLC and NSCLC at presentation
SCLC
Upper limit of Limited Extensive NSCLC
Author ref. normal (ngml-1) (%) (%)
Carney et al. (1982) 12 15/38 (39) 49/56 (87)
Johnson et al. (1984) 20 23/39 (59) 45/54 (83)
Esscher et al. (1985) 12 34/48 (71.8) 54/55 (98.2) 13/51 (25.4)
Ariyoshi et al. (1983, 1984) 10 6/13 (46) 24/27 (88.8) 21/125 (16.8)
Akoun et al. (1985) 10 6/16 (37.5) 22/27 (78.6) 2/14 (14.2)
This study 13.5 25/38 (68.5) 34/39 (68.5) 16/94 (17)
unobtainable. In such a case NSE levels
>25ngml-1, are highly suspicous but not an
infallible diagnostic indicator of SCLC.
Treatment of SCLC by chemotherapy was
followed by a decrease of NSE when it had been
raised at presentation to reach normal levels when
there was clinical evidence of an objective
remission. By contrast the levels in patients who
only had stable disease or failed to respond to
treatment did not normalise. The NSE level was
unaffected by the presence of cerebral metastases if
they were the solitary site of progression of the
disease. All patients except four who had
progressive disease had an exponential rise of NSE,
which could even be detected as it commenced its
rise through the normal range. Retrospectively, the
interval between the first rise of NSE and the
clinical detection of progression varied from 0-112
days (median 42, n=14). This data supports the
report of Johnson et al. (1984) who showed a
persistently raised NSE level in 15 out of 23 (65%)
patients 2-12 weeks (median 4) before clinical
recognition of recurrence. It is of interest that 3 of
the patients, who showed progressive disease
without a rise of NSE, had histologically proven
NSCLC. This indicates that normal NSE levels in a
case of progressive disease warrant further
investigation of the nature of the recurrent tumour.
The relationship between tumour mass and NSE
and response to treatment seen in the present study
is comparable to that reported by Carney et al.
(1982); Ariyoshi et al. (1983; 1984); Pahlman et al.
(1984); Johnson et al. (1984) and Akoun et al.
(1985).
Immunochemical assays for NSE either use an
antisera to human yy enolase (NSE) or depend on
the cross reactivity of anti rat yy enolase (Kato et
al., 1983) or anti mouse yy enolase (Akoun et al.,
1985) antisera with human NSE. However, it is
evident that the serum contains a mixture of the yy
form of enolase and ocy hybrid molecules that cross
react with the antisera to yy enolase. Gerbitz et al.
(1984) have estimated that the serum concentrations
in healthy subjects of the ay and yy enolase were 6.0
+3.2 and 3.3 + 1.5ngml-1 respectively. Kato et al.
(1983) reported the concentrations to be 4.1 + 1.4
and 1.5+0.4ngml-'. In some patients with SCLC
Gerbitz et al. (1984) reported increases of yy enolase
from 2 to 20 fold; minor changes occurred in the ay
enolase level in 6 out of the 7 patients but in 1 of
them the ay form was considerably increased. There
is still uncertainty whether the cross-reactivity is
important in the interpretation of the NSE test. The
present data and published information suggests
that the current tests perform well as indicators of
large tumour burdens.
This study of the Pharmica NSE-RIA test has
again confirmed the potential of NSE as a marker
for the monitoring of SCLC during and especially
after treatment. Further prospective studies will be
needed to determine whether it should be taken
into account when deciding the optimal number of
cycles of chemotherapy that are required, or can be
a reliable and early indicator of recurrence once
chemotherapy has been stopped. The introduction
of commercial NSE assays will help in the build up
of a substantial experience of NSE measurements in
clinical oncology that are needed at this time. No
doubt in lung cancer such an investigation should
not only include SCLC but other forms where the
histological differentiation is equivocal.
We are grateful to Pharmacia Health Care AB, Uppsala,
Sweden for supplying the NSE-RIA kits for evaluation
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